Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series

about

Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series

Item

http://www.wikidata.org/entity/Q58764956

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Clinical benefit of fulvestran ...... d breast cancer: a case series

@en

Clinical benefit of fulvestran ...... d breast cancer: a case series

@nl

type

Item

label

Clinical benefit of fulvestran ...... d breast cancer: a case series

@en

Clinical benefit of fulvestran ...... d breast cancer: a case series

@nl

prefLabel

Clinical benefit of fulvestran ...... d breast cancer: a case series

@en

Clinical benefit of fulvestran ...... d breast cancer: a case series

@nl

P1476

Clinical benefit of fulvestran ...... d breast cancer: a case series

@en

P2093

Adrienne Cserháti

http://www.w3.org/2001/XMLSchema#string

Alíz Nikolényi

http://www.w3.org/2001/XMLSchema#string

Erzsébet Valicsek

http://www.w3.org/2001/XMLSchema#string

Gabriella Uhercsák

http://www.w3.org/2001/XMLSchema#string

Melinda Csenki

http://www.w3.org/2001/XMLSchema#string

Orsolya Rusz

http://www.w3.org/2001/XMLSchema#string

Renáta Kószó

http://www.w3.org/2001/XMLSchema#string

Zsuzsanna Kahán

http://www.w3.org/2001/XMLSchema#string

Ágnes Dobi

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab emtansine: mechanisms of action and drug resistance

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.

Mechanisms of endocrine resistance in breast cancer.

Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer.

P304

5459-5463

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S170736

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30233207

http://www.w3.org/2001/XMLSchema#string

P932

6129034

http://www.w3.org/2001/XMLSchema#string